InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a mo⦠read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
$1.37
Price+1.87%
$0.03
$92.475m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$162.830k
-
1y CAGR-
3y CAGR-
5y CAGR-$45.292m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.73
-
1y CAGR-
3y CAGR-
5y CAGR$57.044m
$73.442m
Assets$16.398m
Liabilities$599.110k
Debt0.8%
-
Debt to EBITDA-$43.167m
-
1y CAGR-
3y CAGR-
5y CAGR